Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Melanotan II crosses your target, drops, or sets a new tracked low—without daily noise.

Price scope Alert me Target per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence 157 certificate records for Melanotan II products, from 72 vendors 109 reference a report on the testing laboratory's own system · 89 have a laboratory lookup that answered when last checked · 138 match a vendor product page at the same address

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

Dermal / cosmetic research

Primary research area: Dermal. Also surfaces under Hormone for browsing and discovery.

Aliases

No major aliases are tracked for this profile yet.

Signal depth

Low

No FDA label signal · 1 trials · 198 PubMed results

Promising

Research evidence

Melanotan II has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Melanotan II has 1 name-matched clinical trial (highest phase: Phase 2) and 198 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.

Human data

Phase 2

Trial quality

Randomized

Outcomes

Surrogate / early

Replication

Multiple papers

Literature

High-impact

PHASE2 · Randomized Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo International Journal of Impotence Research · 118 citations Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II European Journal of Pharmaceutics and Biopharmaceutics · 64 citations Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery Journal of Endocrinology · 56 citations Unabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression Journal Article Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs. Case Reports Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report.

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-03 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What melanotan II is

Melanotan II is a melanocortin analogue that appears frequently in online tanning and cosmetic conversations. It is one of the better-known examples of a peptide with strong consumer curiosity but no FDA-approved status.

Why it matters

It helps define the difference between cosmetic-demand peptides and clinically grounded peptide therapies.

Regulatory context

Melanotan II is not FDA approved in the United States. It belongs in the research-market bucket.

Practical reading note

Because tanning-related demand can blur aesthetic goals and safety assumptions, this is a category where formal approval status matters a lot.